We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Dozens of patient groups penned a letter to CVS Health’s President and CEO Larry Merlo urging the company to scrap its recently announced plan to deny coverage of drugs that fail to meet a certain level of cost-effectiveness. Read More
Generic drugmakers are suing New York state over its law imposing surcharges on distributors and manufacturers of opioids, arguing the tax disproportionately hurts generic manufacturers. Read More
“Several opioid prescribing practices were decreasing before the CDC guideline, but the time of its release was associated with a greater decline,” the study concluded. Read More
Sen. Claire McCaskill (D-Mo.) called on Nostrum Pharmaceuticals, a drugmaker with facilities in Kansas City, to explain a reported 400 percent price hike in its bladder infection treatment, nitrofurantoin. Read More
FDA Commissioner Scott Gottlieb Friday announced a four-pronged agency initiative to take on antimicrobial resistance, in part by creating incentives for drugs that treat it. Read More
One of the most effective ways for the FDA to increase patient access to high quality generics is to offer guidance that promotes the development of cost-saving generics, especially for complex drugs that are difficult to copy, he said. Read More
“Some language suggests that there is the possibility of patient experience data collected outside of pivotal trials to be included in labeling,” Allergan noted, requesting further details on the statistical significance and replication standards the agency expects to be met. Read More
The study, led by University of Oxford researcher Ben Goldacre, found that 32 major universities did not report results for any trials they sponsored. Read More